MGCD265 - Met Inhibitor / Anti-Angiogenesis
Posted: Tue Mar 17, 2009 4:47 pm
FYI. Don't know anything about this drug.
Two recruiting clinical trials: http://clinicaltrials.gov/ct2/show/NCT0 ... 265&rank=1
and http://clinicaltrials.gov/ct2/show/NCT0 ... 265&rank=2
Sites are Vancouver, Duke, and Dana Farber
Second is at Detroit / Karmanos and Texas
Comes from Methygene and open label Phase I.
Targets c-met, Tie-2, RON, and 3 VEGF receptor tyrosine kinases (RTKs).
XL880 is another attempt at met inhibitor + antiangiogenesis, but we have heard that it is a relatively weak met inhibitor, and one ASPS patient that we know of with disseminated disease did not benefit.
Two recruiting clinical trials: http://clinicaltrials.gov/ct2/show/NCT0 ... 265&rank=1
and http://clinicaltrials.gov/ct2/show/NCT0 ... 265&rank=2
Sites are Vancouver, Duke, and Dana Farber
Second is at Detroit / Karmanos and Texas
Comes from Methygene and open label Phase I.
Targets c-met, Tie-2, RON, and 3 VEGF receptor tyrosine kinases (RTKs).
XL880 is another attempt at met inhibitor + antiangiogenesis, but we have heard that it is a relatively weak met inhibitor, and one ASPS patient that we know of with disseminated disease did not benefit.